Clinical Trial Update: A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age [Phase 2]

View source ↗

Summary

Phase 2 trial investigating safety and immunogenicity of different formulations of MenACWY vaccine (GSK3536820A and Menveo) in healthy adolescents and young adu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis
• Meningococcal Disease

Drugs mentioned

• GSK3536820A (GSK3536820A meningococcal ACWY conjugate vaccine formulation)
• Menveo (meningococcal group A, C, W-135 and Y conjugate vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Meningitis, Meningococcal | Phase 2 | Status: COMPLETED | Results posted: 2021-02-17